benign prostatic hyperplasia
Conditions
Interventions
Case series:compound sabal berry tablets
Sponsors
West China Hospital of Sichuan
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. aged > 50 years; 2. the international prostate symptom score (IPSS) score = 13 and the quality of-life (QoL) score = 3; 3. the volume (V) of prostate > 25 mL; 4. Qmax 4 mL/s to 15 mL/s; 5. residual urine (RU) < 200 mL; 6. serum prostate specific antigen (PSA) = 4ng/mL; 7. voluntary participation; and 8. drugs with an effect on micturition function or other forbidden drugs should be stopped at least 2 weeks prior to entry the study. Patients were allowed to enter in this study unless they fulfilled all the above inclusion criteria.
Exclusion criteria
Exclusion criteria: Patients with urination disorder that caused by other diseases, such as prostate cancer, bladder malignancy, neurogenic bladder, urinary dysfunction, bladder stones, recurrent urinary tract infection, recurrent gross hematuria, or large diverticulum, were excluded from the study. In addition, patients who had previous prostate or urethra surgery or patients with other diseases, such as poorly controlled diabetes, cardiovascular disease, and hepatic or renal dysfunction, were excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (IPSS); | — |
Countries
China
Contacts
Public ContactQiang Wei
Department of Urology, West China Hospital of Sichuan
Outcome results
None listed